Molecular Partners (NASDAQ:MOLN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Molecular Partners (NASDAQ:MOLN) in a report published on Monday,Benzinga reports. They currently have a $13.00 price target on the stock.

Several other equities research analysts have also issued reports on MOLN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. JPMorgan Chase & Co. dropped their price objective on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research note on Monday, December 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Stock Up 2.8%

NASDAQ:MOLN opened at $4.34 on Monday. Molecular Partners has a twelve month low of $3.36 and a twelve month high of $5.36. The stock’s 50-day simple moving average is $4.54 and its 200 day simple moving average is $4.18. The firm has a market capitalization of $175.25 million, a PE ratio of -2.18 and a beta of 1.03.

Molecular Partners (NASDAQ:MOLN) last issued its earnings results on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). On average, analysts anticipate that Molecular Partners will post -1.93 EPS for the current fiscal year.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.